Open access
Jul 2026
T-bet CAR T cells: A new avenue for NSCLC therapy analyzed in lung cancer-derived organoids 2258880
This study leverages PDOs as a clinically relevant preclinical model to optimize CAR T design and supports T-bet as a promising axis for developing safer and more durable next generation CAR T therapies against NSCLC.
Lin Li, D. Trufa, Bastian Zinkel et al.
· Journal of Immunology · 0 citations